Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations

<i>Background and Objectives:</i> Although breast cancer is the most common type of cancer among women, bilateral breast cancer (BBC) remains exceedingly rare. BBC can present as either synchronous (SBBC) or metachronous (MBBC) disease. Data regarding the clinical characteristics of BBC...

Full description

Saved in:
Bibliographic Details
Main Authors: Berkan Karabuğa, Mustafa Büyükkör, Ekin Konca Karabuğa, Sedat Yıldız, Mirmehdi Mehtiyev, Havva Yeşil Çınkır, Sıla Soylu Koçoğlu, Hacer Demir, Ozan Yazıcı, Doğan Uncu, Ömür Berna Öksüzoğlu, Ülkü Yalçıntaş Arslan
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/6/1029
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850167809015808000
author Berkan Karabuğa
Mustafa Büyükkör
Ekin Konca Karabuğa
Sedat Yıldız
Mirmehdi Mehtiyev
Havva Yeşil Çınkır
Sıla Soylu Koçoğlu
Hacer Demir
Ozan Yazıcı
Doğan Uncu
Ömür Berna Öksüzoğlu
Ülkü Yalçıntaş Arslan
author_facet Berkan Karabuğa
Mustafa Büyükkör
Ekin Konca Karabuğa
Sedat Yıldız
Mirmehdi Mehtiyev
Havva Yeşil Çınkır
Sıla Soylu Koçoğlu
Hacer Demir
Ozan Yazıcı
Doğan Uncu
Ömür Berna Öksüzoğlu
Ülkü Yalçıntaş Arslan
author_sort Berkan Karabuğa
collection DOAJ
description <i>Background and Objectives:</i> Although breast cancer is the most common type of cancer among women, bilateral breast cancer (BBC) remains exceedingly rare. BBC can present as either synchronous (SBBC) or metachronous (MBBC) disease. Data regarding the clinical characteristics of BBC are limited. In this study, we aimed to share our multicenter, retrospective experience on the clinicopathological and demographic features of SBBC and MBBC, their survival outcomes, and the factors influencing survival, in light of current knowledge. <i>Material and Method:</i> A total of 125 patients who were treated and followed between 2015 and 2024 across six different centers were included in the study. The patients were categorized into synchronous (SBBC) and metachronous (MBBC) groups. Their clinicopathological characteristics were analyzed, along with disease-free survival (DFS) and 5-year overall survival (OS) outcomes. <i>Results:</i> DFS was 5.7 years in the SBBC group and 5.6 years in the MBBC group (<i>p</i> = 0.95). The 5-year OS rate was 95.2% in the MBBC group and 80.7% in the SBBC group (<i>p</i> = 0.035). Hormone receptor negativity was identified as an independent risk factor for lower DFS in the overall patient cohort (HR: 0.55, 95% CI: 0.31–0.98, <i>p</i> = 0.04). <i>Conclusion:</i> Significant differences were found between the SBBC and MBBC groups in terms of hormone receptor status, presence of an invasive lobular carcinoma component, recurrence/metastasis status, and molecular subtype discordance between the two primary tumors. Although DFS did not significantly differ between the groups, the 5-year OS was significantly higher in the MBBC group. In multivariate regression analysis, hormone receptor negativity was identified as an independent risk factor for decreased DFS among all BBC patients. Our study is noteworthy for shedding light on the clinical features of BBC in the context of current knowledge and for its multicenter design.
format Article
id doaj-art-dba23d01ac9c4d1a88904ca2018ba0cc
institution OA Journals
issn 1010-660X
1648-9144
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-dba23d01ac9c4d1a88904ca2018ba0cc2025-08-20T02:21:07ZengMDPI AGMedicina1010-660X1648-91442025-06-01616102910.3390/medicina61061029Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical ObservationsBerkan Karabuğa0Mustafa Büyükkör1Ekin Konca Karabuğa2Sedat Yıldız3Mirmehdi Mehtiyev4Havva Yeşil Çınkır5Sıla Soylu Koçoğlu6Hacer Demir7Ozan Yazıcı8Doğan Uncu9Ömür Berna Öksüzoğlu10Ülkü Yalçıntaş Arslan11Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, TurkeyDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, TurkeyDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, TurkeyDepartment of Medical Oncology, Ankara Bilkent City Hospital, Ankara 06800, TurkeyDepartment of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep 27310, TurkeyDepartment of Medical Oncology, Gazi University Faculty of Medicine, Ankara 06560, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, TurkeyDepartment of Medical Oncology, Gazi University Faculty of Medicine, Ankara 06560, TurkeyDepartment of Medical Oncology, Ankara Bilkent City Hospital, Ankara 06800, TurkeyDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, TurkeyDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey<i>Background and Objectives:</i> Although breast cancer is the most common type of cancer among women, bilateral breast cancer (BBC) remains exceedingly rare. BBC can present as either synchronous (SBBC) or metachronous (MBBC) disease. Data regarding the clinical characteristics of BBC are limited. In this study, we aimed to share our multicenter, retrospective experience on the clinicopathological and demographic features of SBBC and MBBC, their survival outcomes, and the factors influencing survival, in light of current knowledge. <i>Material and Method:</i> A total of 125 patients who were treated and followed between 2015 and 2024 across six different centers were included in the study. The patients were categorized into synchronous (SBBC) and metachronous (MBBC) groups. Their clinicopathological characteristics were analyzed, along with disease-free survival (DFS) and 5-year overall survival (OS) outcomes. <i>Results:</i> DFS was 5.7 years in the SBBC group and 5.6 years in the MBBC group (<i>p</i> = 0.95). The 5-year OS rate was 95.2% in the MBBC group and 80.7% in the SBBC group (<i>p</i> = 0.035). Hormone receptor negativity was identified as an independent risk factor for lower DFS in the overall patient cohort (HR: 0.55, 95% CI: 0.31–0.98, <i>p</i> = 0.04). <i>Conclusion:</i> Significant differences were found between the SBBC and MBBC groups in terms of hormone receptor status, presence of an invasive lobular carcinoma component, recurrence/metastasis status, and molecular subtype discordance between the two primary tumors. Although DFS did not significantly differ between the groups, the 5-year OS was significantly higher in the MBBC group. In multivariate regression analysis, hormone receptor negativity was identified as an independent risk factor for decreased DFS among all BBC patients. Our study is noteworthy for shedding light on the clinical features of BBC in the context of current knowledge and for its multicenter design.https://www.mdpi.com/1648-9144/61/6/1029bilateral breast cancersynchronousmetachronous
spellingShingle Berkan Karabuğa
Mustafa Büyükkör
Ekin Konca Karabuğa
Sedat Yıldız
Mirmehdi Mehtiyev
Havva Yeşil Çınkır
Sıla Soylu Koçoğlu
Hacer Demir
Ozan Yazıcı
Doğan Uncu
Ömür Berna Öksüzoğlu
Ülkü Yalçıntaş Arslan
Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations
Medicina
bilateral breast cancer
synchronous
metachronous
title Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations
title_full Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations
title_fullStr Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations
title_full_unstemmed Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations
title_short Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations
title_sort illuminating bilateral breast cancer a multicenter experience and clinical observations
topic bilateral breast cancer
synchronous
metachronous
url https://www.mdpi.com/1648-9144/61/6/1029
work_keys_str_mv AT berkankarabuga illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT mustafabuyukkor illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT ekinkoncakarabuga illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT sedatyıldız illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT mirmehdimehtiyev illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT havvayesilcınkır illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT sılasoylukocoglu illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT hacerdemir illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT ozanyazıcı illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT doganuncu illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT omurbernaoksuzoglu illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations
AT ulkuyalcıntasarslan illuminatingbilateralbreastcanceramulticenterexperienceandclinicalobservations